Cancer pain is one of the most frequent and debilitating symptoms in patients with cancer.
1-5 Opioids are the mainstay for cancer pain management. Currently, the use of opioids for cancer pain is suboptimally managed despite their need. Various contributing factors play a role in suboptimal use of opioids; these include limited education, variable access due to opioid shortages, and the need for opioid preauthorization, which is the result of the ongoing opioid epidemic in the US. The US government enacted restrictive legislation on opioid access, which indirectly affected clinical cancer pain management.
1-5 Nonmedical opioid use (NMOU), ie, the use of opioids without a prescription or in ways other than medically prescribed, is common and may significantly affect cancer pain management. Nonmedical opioid use is trending to be one of the main concerns in pain management in the opioid crisis in patients both with and without cancer.
6-14 In patients without cancer, NMOU is associated with negative health outcomes and overdose deaths.
15-17 However, in oncology, the best practices for identifying and optimally managing NMOU are not yet clearly defined.
12,18,19 Prior studies by our team and others were also able to establish the risk factors for NMOU in patients with cancer, but not all the patients with risk factors will be diagnosed with having NMOU behaviors, and some patients with no previous risk factors will engage in NMOU behaviors.
20,21 Nonmedical opioid use behaviors may have long-term, devastating consequences for patients with cancer, including increased morbidity and mortality due to the possible development of substance use disorder, poor management of their cancer from lack of preventive and adherence practices to cancer treatments, and from the comorbidities (ie, mood disorders, insomnia) that accompany this condition.
22-24 Hence, there is a need to develop optimal guidelines to screen and manage NMOU in patients with cancer.
25,26 Nonmedical opioid use manifests in a range of behaviors, including early refill requests (self-escalation of opioids), resistance to prescription changes, opioid sharing between friends and family, requests for specific drugs, obtaining opioids from multiple physicians, using nonprescribed drugs, using opioids for nonprescribed indications (eg, anxiety, insomnia), family members expressing concern over the patient’s opioid use, discrepancy in pill counts, concurrent abuse of illicit drugs, impaired functioning per family or staff, prescription forgery, “lost or stolen” medications, and the selling or stealing of prescription drugs.
19 One of the main aims of research on NMOU is to reduce the frequency of NMOU behaviors with interventions such as universal screening, reduced opioid exposure, and more intense follow-up of patients with elevated risk. Unfortunately, the absence of data on the frequency of NMOU behavior is the major barrier to conducting research on interventions to reduce NMOU. Additionally, there are no studies, to our knowledge, evaluating the independent predictors for NMOU behavior. Therefore, the aims of this study were to determine the overall frequency of NMOU behavior and to examine the independent predictors for NMOU behavior.